Last reviewed · How we verify
Commercial vaccine 2
At a glance
| Generic name | Commercial vaccine 2 |
|---|---|
| Also known as | Fluarix Tetra (quadrivalent) |
| Sponsor | Crucell Holland BV |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma (PHASE3)
- A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection (PHASE1, PHASE2)
- Clinical Trial for Batch Consistency of EV71 Vaccine (PHASE4)
- Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (PHASE1)
- Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). (PHASE3)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Commercial vaccine 2 CI brief — competitive landscape report
- Commercial vaccine 2 updates RSS · CI watch RSS
- Crucell Holland BV portfolio CI